PACB — Pacific Biosciences of California, Inc.

Summary of PACB Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $44.6 million, a 14% increase year-over-year and a 16% increase quarter-over-quarter.
• Full Year Revenue: $160 million, representing 4% growth from 2024.
• Consumables Revenue: Grew 15% year-over-year in Q4, reaching a record $21.6 million; full-year consumables revenue increased 16% to $82 million.
• Instrument Revenue: Increased 13% in Q4 to $17.3 million, but decreased 18% for the full year to $53.8 million due to lower Revio shipments.
• Non-GAAP Gross Margin: Improved to 40% in Q4 from 31% in Q4 2024, and also up from 33% for the full year 2024.
• Net Loss: Non-GAAP net loss of $37.6 million in Q4 ($0.12 per share), down from $55.3 million in Q4 2024. Full-year net loss was $158.8 million ($0.53 per share), improved from $228 million in 2024.
• Cash Position: Ended the year with approximately $280 million in cash and investments.

2. Strategic Updates and Business Highlights

• Record Consumables Revenue: Achieved all-time high consumable revenue, with significant growth in clinical applications, particularly in rare disease genomics.
• Instrument Shipments: Shipped 21 Revio and 42 Vega systems in Q4, with cumulative shipments reaching 331 Revio and 147 Vega systems.
• Clinical Market Growth: Notable 55% growth in consumables for clinical and hospital customers in 2025, driven by whole genome sequencing applications.
• Product Development: Announced the upcoming launch of SparkNex, a new consumable chemistry expected to improve economics and throughput, with a target price of under $300 per genome.
• International Expansion: Strong growth in EMEA, with a 45% increase in revenue in Q4, attributed to clinical adoption and Vega instrument sales.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be in the range of $165 million to $180 million, representing approximately 8% growth at the midpoint.
• Gross Margin Improvement: Anticipated increase of 100 to 400 basis points in non-GAAP gross margin, driven by higher consumables mix and the introduction of SparkNex.
• Operational Focus: Continued emphasis on cost management and operational efficiency, with expectations for slightly improved non-GAAP operating expenses compared to 2025.

4. Bad News, Challenges, or Points of Concern

• Academic Funding Pressure: Ongoing challenges in the academic funding environment are expected to persist, impacting instrument sales.
• Instrument Revenue Decline: Significant decrease in instrument revenue for the full year, primarily due to lower Revio system shipments.
• Component Cost Volatility: Potential headwinds from volatility in component costs, particularly memory, which could affect gross margins.
• Market Dynamics: The company faces competition from other sequencing technologies, and the transition to SparkNex may introduce short-term variability in demand.

5. Notable Q&A Insights

• Revio Pull-Through: Expected to remain stable, with SparkNex potentially increasing utilization without significantly altering pull-through metrics.
• International Growth: Anticipated strong clinical growth outside the U.S., particularly in EMEA, but no significant budget flush observed in Q4.
• Multi-System Orders: Increasing trend in multi-system orders expected, but pricing strategies will be carefully managed to balance ASP and consumable revenue.
• Operational Expense Management: Focus on managing G&A and R&D expenses while maintaining investment in critical programs to support growth.

This summary encapsulates the key points from the earnings call, highlighting PACB's financial performance, strategic initiatives, outlook for the coming year, and challenges faced in the current market environment.